Battling cancer is undoubtedly one of life's toughest fights, but what if exercise could be a powerful ally in this battle? The Alliance for Clinical Trials in Oncology is launching a groundbreaking study called DEFEND, and it's set to revolutionize how we support cancer patients undergoing chemotherapy. This study is designed to test a telehealth exercise program, bringing fitness directly to patients' homes.
The DEFEND trial (Alliance A222302) focuses on individuals aged 18 to 65 who are receiving chemotherapy with the goal of a cure. The core idea? To see if virtual exercise sessions, encompassing supervised resistance and aerobic training, can be successfully delivered during treatment. The study aims to determine if this approach helps patients maintain their physical function, reduce fatigue, and prevent disability. This is critical data that will help shape a larger, phase III trial.
"Unlike traditional in-person programs, DEFEND aims to leverage telemedicine," explains Dr. Jennifer Ligibel, a key figure in the study. Participants will engage in twice-weekly supervised exercise sessions via video calls, guided by trained staff. They'll also complete additional aerobic sessions independently, with remote support.
Participants will receive resistance bands, a stationary bike, and a Fitbit to track their activity. They'll work with an oncology-trained exercise coach based at the Dana-Farber Cancer Institute.
"Our hybrid model aims to overcome common barriers to exercise," says Dr. Kathryn Schmitz, another lead researcher. By offering a home-based approach, the study hopes to make physical activity more accessible for a diverse group of cancer patients.
The primary goal of the DEFEND trial is to determine the feasibility of this virtual exercise intervention. Secondary goals include assessing participant recruitment and retention, particularly from rural areas and underserved communities. Researchers will also explore changes in physical function, like grip strength and walking distance, along with self-reported physical activity levels. They will also look at patient-reported outcomes and employment status over time.
This study builds on a growing body of evidence highlighting the benefits of exercise for cancer patients, including reducing treatment side effects and improving quality of life. But here's where it gets controversial: few studies have tested scalable, remote delivery models that could be integrated into routine oncology care.
The DEFEND trial is particularly timely, as healthcare systems embrace telehealth. If successful, this study could pave the way for broader adoption of virtual exercise programs as a standard part of cancer treatment.
The trial is expected to begin enrolling participants in late 2025, with primary completion anticipated by January 2027. The exercise program will run throughout the chemotherapy period, up to a maximum of six months. Participants will undergo assessments at the beginning, end, and three months after chemotherapy.
About the Alliance for Clinical Trials in Oncology:
The Alliance for Clinical Trials in Oncology is a national leader in cancer research, with over 25,000 specialists at 115 main institutions and 1,400 affiliates. They conduct groundbreaking clinical trials that improve outcomes and change standards of care. Their work has led to multiple FDA approvals and influenced national guidelines. More than 40,000 participants have taken part in Alliance studies.
What are your thoughts? Do you think virtual exercise programs could become a standard part of cancer treatment? Share your opinions in the comments below!
